Antiemetic therapy in cancer: an update.
Although nausea and vomiting are widely recognised as two of the most distressing symptoms of cytotoxic therapy, there is still concern over the adequate control of these symptoms in the cancer population. Recently updated Antiemetic Consensus Guidelines recommend the prophylactic treatment of all patients at moderate-to-high risk of experiencing nausea and vomiting following chemotherapy and radiotherapy. It is important that these guidelines are fully adhered to; however, when considering which antiemetic regimen is most appropriate in an individual patient, it is also important to consider individual patient-related factors. In addition, certain patient groups, such as the young or the elderly, may be in need of specific consideration due to age-related factors that may influence treatment decisions.
Horiot
Jean-Claude
JC
Centre de Lutte contre le Cancer GF Leclerc, 1 rue Marion, BP 77980, Dijon, 21079, France. horiotjc@dijon.fnclcc.fr
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D044406:Receptors, Serotonin, 5-HT3 / Q000502:physiology; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D044406:Receptors, Serotonin, 5-HT3; D058831:Serotonin 5-HT3 Receptor Antagonists; D012702:Serotonin Antagonists